Tipiracil

Tipiracil is a thymidine phosphorylase (TPase) inhibitor.

Product Specifications

CAS Number

[183204-74-2]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Nucleoside Antimetabolite/Analog; Thymidylate Synthase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Tipiracil.html

Purity

99.98

Solubility

DMSO : < 1 mg/mL (ultrasonic; warming) |H2O : 1 mg/mL (ultrasonic)

Smiles

O=C1NC(C(Cl)=C(CN2C(CCC2)=N)N1)=O

Molecular Formula

C9H11ClN4O2

Molecular Weight

242.66

Precautions

H315, H319, H320

References & Citations

[1]Lee SJ, et al. Thymidine phosphorylase influences [ (18) F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jul;41 (7) :1327-35.|[2]Raedler LA. Lonsurf (Trifluridine plus Tipiracil) : A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer. Am Health Drug Benefits. 2016 Mar;9 (Spec Feature) :97-100.|[3]Tanaka N, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014 Dec;32 (6) :2319-26.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

Launched

Citation 01

Oncol Rep. 2023 Mar;49 (3) :52.|Biomed Pharmacother. 2021 Jul:139:111672.|J Mol Med (Berl) . 2019 Aug;97 (8) :1183-1193.|Mod Rheumatol. 2018 May;28 (3) :495-505.|Patent. US Patent 11110111.